Shots: The P-II FIGHT-202 (NCT02924376) study involves assessing of pemigatinib (13.5 mg, qd) as monothx in adults patients previously treated, LA or metastatic cholangiocarcinoma with documented FGF/FGFR status divided into […]readmore
Tags : FIGHT-202 Trial
Latest Posts
Categories
Related Topics
AbbVie
Acceptance
Acquire
Agreement
Amgen
approval
AstraZeneca
Bayer
Biosimilar
BMS
Boehringer Ingelheim
Collaborates
Collaboration
Commercialize
COVID-19
Develop
Development
Eli Lilly
Exclusive
FDA
Gilead
GSK
Janssen
Launches
License
License Agreement
Lilly
Merck
Novartis
P-III
patients
Pfizer
receives
Regeneron
Report
reports
results
Roche
Sanofi
Signs
study
Takeda
Treat
Treatment
US